ArkVax

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. ArkVax is based in London, United Kingdom and was founded in 2020.

Last price · $/share

—

Implied valuation

—

Total raised

—

Last round

—

Funding — no rounds on record

No funding rounds for ArkVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of ArkVax with a free account

·Watch ArkVax: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

ArkVax investors

6 investors are on record for ArkVax, including Future Planet Capital, UK Innovation & Science Seed Fund, Biotechnology and Biological Sciences Research Council and Accelerate@Babraham.

For fundraisers

Raising for a company like ArkVax?

6 investors have backed ArkVax.

See all 6 investors →